ANEB
Anebulo Pharmaceuticals, Inc.2.2300
+0.0200+0.91%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
91.62MP/E (TTM)
-Basic EPS (TTM)
-0.22Dividend Yield
0%Recent Filings
8-K
10-Q
8-K
Going private update with alternatives
Anebulo Pharmaceuticals updated its proposed going private transaction, announced July 23, 2025, after receiving inbound interest from potential financial and strategic partners. The board is reviewing alternatives like asset sales or mergers to maximize stockholder value, while planning a special meeting for the related reverse stock split. No timetable exists; outcomes remain uncertain amid regulatory and board discretion risks.
8-K
Anebulo plans reverse split to go private
Anebulo Pharmaceuticals announced a reverse stock split on July 23, 2025, at a ratio between 1-for-2,500 and 1-for-7,500, pending stockholder approval at an August 22 meeting, to slash its record holders below 300 and go private by deregistering with the SEC. Small shareholders with fewer than the minimum shares—2,500 to 7,500—will receive $3.50 per pre-split share in cash, exiting entirely, while larger holders retain reduced stakes. This move cuts public reporting burdens, freeing resources for product development and cost reductions. The board can still abandon it if interests shift.
8-K
Anebulo's Q3 loss steady
Anebulo Pharmaceuticals reported a Q3 fiscal 2025 net loss of $1.7 million, matching last year's figure but with per-share loss narrowing to $(0.04) from $(0.06) on higher share count. Operating expenses rose to $1.9 million from $1.7 million, driven by general and administrative costs, while cash stood at $13.3 million as of March 31, 2025, bolstered by a $3 million loan facility. The company advances intravenous selonabant for pediatric cannabis toxicity, planning Phase 1 dosing in healthy adults this Q3 2025. FDA backs the unmet need, yet clinical risks loom large.
ANNX
Annexon, Inc.
4.80-0.11
ANRO
Alto Neuroscience, Inc.
17.10+0.07
ANTX
AN2 Therapeutics, Inc.
1.16-0.01
ANVS
Annovis Bio, Inc.
3.93+0.15
CERO
CERo Therapeutics Holdings, Inc
0.09-0.01
CNBX
CNBX Pharmaceuticals Inc.
0.00+0.00
ENVB
Enveric Biosciences, Inc.
5.24-0.12
KLTO
Klotho Neurosciences, Inc.
0.39+0.01
NBTX
Nanobiotix S.A.
22.32+0.18
NNNN
Anbio Biotechnology
28.01-0.39